Advertisement

Malignant Hyperthermia

  • E. P. Verrengia
Chapter
Part of the Emergency Management in Neurology book series (EMN)

Abstract

Malignant Hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle, a “pharmacogenetics” myopathy [1, 2]. Patients are predisposed to develop a serious state of muscle hypermetabolism during general anaesthesia, such as halogen-containing volatile anaesthetics and/or succinylcholine.

References

  1. 1.
    Rosero EB, Adesanya AO, Timaran CH, Joshi GP (2009) Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 110:89–94CrossRefPubMedGoogle Scholar
  2. 2.
    Rosenberg H, Davis M, James D, Pollock N, Stowell K (2007) Malignant hyperthermia. Orphanet J Rare Dis 2:21. doi: 10.1186/1750-1172-2-21 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N (2014) Malignant hyperthermia in Canada: characteristics of index anaesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg 118(2). www.anaesthesia-analgesia.org
  4. 4.
    Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB (2010) Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 110:498–507CrossRefPubMedGoogle Scholar
  5. 5.
    de Carvalho Correia AC, Silva PCB, da Silva BA (2012) Malignant hyperthermia: clinical and molecular aspects. Rev Bras Anestesiol 62(6):820–837CrossRefGoogle Scholar
  6. 6.
    Bandschapp O, Girard T (2012) Malignant hyperthermia. Swiss Med Wkly 142:w13652PubMedGoogle Scholar
  7. 7.
    Fiszer D, Shaw M-A, Fisher NA, Carr IM, Gupta PK, Watkins EJ, de Sa DR, Kim JH, Hopkins PM (2015) Next-generation sequencing of RYR1 and CACNA1S in malignant hyperthermia and exertional heat illness. Anesthesiology 122:1033–1046CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hopkins PM, Rüffert H, Snoeck MM, Girard T, Glahn KPE, Ellis FR, Müller CR, Urwyler A on behalf of the European Malignant Hyperthermia Group (2015) European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesthesia 115(4):531–9Google Scholar
  9. 9.
    Marilyn Green Larach, Barbara W. Brandom, Gregory C. Allen, Gerald A. Gronert, Erik B. Lehman (2014) Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007–2012: a report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. 119(6). www.anaesthesia-analgesia.org
  10. 10.
    Larach MG et al (1994) A clinical grading scale to predicate malignant hyperthermia susceptibility. Anesthesiology 80:771–779CrossRefPubMedGoogle Scholar
  11. 11.
    Schneiderbanger D, Johannsen S, Roewer N, Schuster F (2014) Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag 10:355–362PubMedPubMedCentralGoogle Scholar
  12. 12.
    Migita T, Mukaida K, Kawamoto M, Kobayashi M, Yuge O (2007) Fulminant-type malignant hyperthermia in Japan: cumulative analysis of 383 cases. J Anesth 21:285–288CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of NeurologyASST Grande Ospedale Metropolitano NiguardaMilanItaly

Personalised recommendations